Here are updates on two of your buys: AbbVie and Amazon

Article Excerpt

Long-time readers know that we aim to keep you informed of important news about the stocks we cover. That means highlighting developments and plans that promise to bolster investor gains. Here are two buys that stand out this month: ABBVIE INC., $197.35, is a buy. The company (New York symbol ABBV; TSINetwork Rating: Above Average) (www.abbvie.com; Shares outstanding: 1.8 billion; Market cap: $348.4 billion; Dividend yield: 3.3%) claimed the leading spot last year for TV drug ad spending; specifically, for commercials promoting its immunology blockbusters. AbbVie’s Skyrizi claimed first place with nearly $377 million spent on 20 separate ads for the drug. As well, with two other drugs in the top 10, the company was far and away the biggest TV drug ad spender of 2024. Similar to 2023’s results, the 2024 list features AbbVie’s Skyrizi and Rinvoq in the top two spots, followed by immunology giants, Sanofi and Regeneron in third place with their joint Dupixent drug. In total, the drugmaker spent $2.13 billion in 2024…